Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intepirdine Extension in DLB
NCT02928445Phase 3Terminated
- Sponsor
- Sio Gene Therapies
- Start
- Oct 2016
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, double-blind trial of intepirdine in dementia with Lewy bodies (DLB) (2 arms), sponsored by Sio Gene Therapies. Primary endpoint: Incidence of adverse events and changes in physical examinations, vital sign measurements, electrocardiograms (ECGs), and clinical laboratory assessments at 24 weeks. Started Oct 2016; status: terminated.
02
Drugs
intepirdine
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on NCT02928445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02928445.